Posts

Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
arcticnovartis

  • Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in patients with stage II or III HR+/HER2- early breast cancer (EBC), consistent across all subgroups1,2
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
arcticnovartis

  • Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data
  • Late-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presented
Biologist to Head-hunter

Biologist to Head-hunter
mihai_novartis

Addressing unmet needs for inherited neuromuscular diseases

Addressing unmet needs for inherited neuromuscular diseases
angilma1

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Novartis ranks first in 2024 Access to Medicine Index

Novartis ranks first in 2024 Access to Medicine Index
arcticnovartis

  • The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics
  • Novartis malaria access plans, widespread registration of products in LMICs, and inclusive business model to improve access to products in multiple countries were all highlighted as Best Practice across the industry
  • Novartis has risen three places to secure the top spot on the 2024 Access to Medicine Index
Official partner of the Eurovision Song Contest 2025

Official partner of the Eurovision Song Contest 2025
weberfr8

Official partner of the Eurovision Song Contest 2025

Official partner of the Eurovision Song Contest 2025
weberfr8

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR